CClinicalTrials.gg
RecruitingNCT06807762Updated Mar 21, 2025

Safety and Pharmacokinetics of Extrato de Cannabis Sativa GreenCare

A Phase 1 interventional study of Cannabis oil in Healthy, sponsored by GreenCare Pharma. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by GreenCare Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 6 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this Phase I clinical trial is to assess the pharmacokinetic availability and safety and tolerability profile of Extrato de Cannabis sativa GreenCare 79.14 mg/mL. The main question it aims to answer is:

  • Is the Extrato de Cannabis sativa GreenCare 79,14 mg/mL safe?
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

This is the only study on the registry with GreenCare Pharma as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Men and women from 18 to 65 years, inclusive;
  • Body weight ≥ 50 kg and BMI between 18.5 and 30 kg/m2, inclusive;
  • Be healthy according to medical history, i.e., have laboratory test results within normal ranges and/or any deviations from normal classified as clinically insignificant;
  • Be exclusively participating in this clinical study during the research period;
  • Understand and comply with the protocol requirements and consent to participate in the study by signing the Informed Consent Form (ICF) approved by an Ethics Committee (EC).

Exclusion criteria

Exclusion Criteria:

Having participated in any experimental study or ingested any experimental drug within 1 (one) year prior to the start of this study;

  • Inability to use oral medication and/or cooperate with investigators due to cognitive impairment or mental state;
  • Reported allergy to any component of Cannabis sativa extract 79.14 mg/mL;
  • Personal or first-degree family history of schizophrenia, bipolar affective disorder, psychotic symptoms, suicidal ideation, planning and/or attempt, and/or severe uncontrolled psychiatric comorbidities, at the discretion of the principal investigator;
  • Donated blood within four (4) months prior to signing the Informed Consent Form (ICF);
  • Being pregnant, breastfeeding, intending to become pregnant during the study period, or having a positive result for urinary β-HCG testing;
  • Reported use of Cannabis and/or its derivatives for any purpose in the past 6 months;
  • Personal history of Cannabis use disorder and/or other illicit drug use disorder;
  • Personal history of alcohol, tobacco, opioid, benzodiazepine, barbiturate, and/or other substance use disorders, such as St. John's Wort;
  • Smokers or ex-smokers who quit less than 6 months ago;
  • Consumed alcoholic beverages within 24 hours before the study confinement period;
  • Any condition that prevents participation at the discretion of the investigator;
  • Dietary habits that prevent ingestion of the diet provided during the study;
  • Any clinical or laboratory finding or therapy that, at the investigator's discretion, may place the participant at risk or interfere with study objectives or outcomes;
  • Non-compliance with the complete ingestion of the diet provided - determination at the discretion of the responsible physician.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Extrato de Cannabis sativa GreenCare 79.14 mg/mL

    Concentration unit: 79.14 mg/mL

    Drug: Cannabis oil

Interventions

  • DrugCannabis oil

    Healthy subjects will be treated with a solution of Cannabis sativa extract diluted in MCT oil, at doses ranging from 39.62 mg to 791.4 mg. This protocol will be divided into two stages: Stage 1 - Determination of the Maximum Tolerated Dose (MTD): Participants (n=60) will be dynamically randomized and will receive Cannabis sativa extract (GreenCare, 79.14 mg/mL) as a single dose after breakfast, with doses ranging from 39.62 mg to 791.4 mg. Stage 2 - Assessment of the MTD: All participants (n=12) will receive the MTD determined in Stage 1, administered in two daily doses for 14 consecutive days.

    Also known as: Extrato de Cannabis sativa GreenCare 79.14 mg/mL

06

What researchers measure

Primary outcomes

  1. Identification of the Maximum Tolerated Dose (MTD) of Cannabis sativa Extract GreenCare 79,14 mg/mL

    Time frame: Up to 5 days

Secondary outcomes

  1. Frequency, intensity, and severity of adverse events

    Time frame: Up to 5 days

  2. Plasma concentrations of CBD and THC

    Time frame: Up to 5 days

07

Study locations

1 of 1 sites recruiting
  • GreenCare Pharma
    Vinhedo, Sao Paulo 13288006, Brazil
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06807762
Lead sponsor
GreenCare Pharma
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Mar 18, 2025
Primary completion
Jun 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 21, 2025

Study contacts

Fabio Furtado
Contact
fabio.furtado@greencarepharma.com.br
+5511942562895
Helena Joaquim, MsC, PhD
Contact
helena.joaquim@greencarepharma.com.br
+5511942562895
Fernando Pacheco, MD
principal investigator · Synvia Clinical | CAEP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion